BIIB033 Single Ascending Dose Study in Healthy Volunteer Subjects

Completed · Phase 1 · Has a placebo group

Conditions studied: Healthy

In brief

The primary objective of the study is to evaluate the safety and tolerability of single dose of BIIB033 administered to healthy adult volunteers.

Key facts

Study ID

NCT01052506

Run by

Biogen

People needed

72

Starts

2010-01-01

Expected to finish

2011-10-01

Last updated by the study team

2017-01-09

Who can join

Age: 25 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Must be in good health
• BMI of 18-30kg/m2
• Contraception required for at least 6 months after study drug administration

You may not qualify if…

• History of clinically significant disease or lab values
• Females of childbearing potentials
• Contraindication to brain MRI and/or lumbar puncture
• Treatment with any prescription medication within the 28 days prior to study entry
• Treatment with any over-the-counter products, including herbal and/or alternative health preparations and procedures within the 14 days prior to study entry
• Regular use of any tobacco product within 3 months prior to study entry

Where it is running

• Research Site — Glendale, California, United States
• Research Site — Utrecht, Netherlands

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.